Apogee Therapeutics, Inc. Common Stock Total Assets
Apogee Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) holds total assets worth $1.34 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Apogee Therapeutics, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Apogee Therapeutics, Inc. Common Stock (2022–2025)
Total assets of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Apogee Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Apogee Therapeutics, Inc. Common Stock (APGE) share price today for real-time trading data and today's change.
Apogee Therapeutics, Inc. Common Stock - Asset Composition Analysis
Apogee Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2025)
Apogee Therapeutics, Inc. Common Stock total assets breakdown as of December 2025. Apogee Therapeutics, Inc. Common Stock's total assets of $1.34 Billion consist of 79.1% current assets and 20.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.0% |
| Accounts Receivable | $5.96 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Apogee Therapeutics, Inc. Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apogee Therapeutics, Inc. Common Stock's current assets represent 79.1% of total assets in 2025, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, down from 99.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Apogee Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Apogee Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Apogee Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.44 | 16.36 | 15.24 |
| Quick Ratio | 26.44 | 16.36 | 15.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $954.22 Million | $484.57 Million | $142.07 Million |
Apogee Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Apogee Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.56 |
| Latest Market Cap to Assets Ratio | 8.97 |
| Asset Growth Rate (YoY) | 24.3% |
| Total Assets | $937.13 Million |
| Market Capitalization | $8.40 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Apogee Therapeutics, Inc. Common Stock's assets at a significant premium (8.97x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Apogee Therapeutics, Inc. Common Stock's assets grew by 24.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $937.13 Million | +24.30% |
| 2024-12-31 | $753.95 Million | +87.83% |
| 2023-12-31 | $401.40 Million | +163.99% |
| 2022-12-31 | $152.06 Million | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chr… Read more